Plasma Protein Therapeutics Market Expected To Grow At 7.2% CAGR Through 2030: What Businesses Need To Know
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
#Plasma Protein Therapeutics Market Growth From $37.08 Billion In 2026 To $48.98 Billion By 2030 At A CAGR Of 7.2%#_x000D_
The plasma protein therapeutics market has experienced significant expansion in recent years. Its valuation is projected to increase from $34.68 billion in 2025 to $37.09 billion in 2026, at a compound annual growth rate (CAGR) of 6.9%. This historical growth can be ascribed to factors such as the increasing prevalence of primary immunodeficiency disorder, the rising demand for immunoglobulin therapies, a constrained plasma donation infrastructure, advancements in protein purification technologies, and regulatory approvals for plasma-derived therapies._x000D_
_x000D_
The plasma protein therapeutics market is projected to experience robust expansion over the coming years. It will grow to $48.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. This anticipated growth is driven by factors such as an increase in recombinant albumin and coagulation factors, the broader adoption of subcutaneous administration techniques, rising healthcare spending in developing economies, innovations in precision medicine, and a surge in public-private partnerships for collecting plasma. Key trends expected during this period involve the creation of personalized plasma protein therapies, the growth in recombinant protein manufacturing, a greater embrace of subcutaneous administration, heightened understanding of uncommon blood conditions, and improvements in supply chain and cold chain management._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Plasma Protein Therapeutics Market Growth Factors Behind Sustained Expansion#_x000D_
The expanding occurrence of autoimmune disorders is anticipated to stimulate the growth of the plasma protein therapeutics market in the future. An autoimmune disorder describes a state where the body’s immune system wrongly attacks and harms its own healthy cells. Therapeutic plasma exchange is employed to manage these autoimmune diseases, which manifest when the body mistakes a part of itself as foreign and produces proteins, known as autoantibodies, that target the misidentified body part. For instance, in May 2023, research conducted by the University of Glasgow, a UK-based public university, involving 22 million people, discovered that autoimmune disorders impact about 10% of the UK’s population, a figure higher than previous estimates from 2022. Consequently, the increasing prevalence of autoimmune disorders is driving the growth of the plasma protein therapeutics market going forward._x000D_
_x000D_
#Plasma Protein Therapeutics Market Segment Breakdown: Which Categories Lead On Revenue?#_x000D_
The plasma protein therapeutics market covered in this report is segmented – _x000D_
_x000D_
1) By Product: Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products_x000D_
2) By Route Of Administration: Intravenous, Subcutaneous_x000D_
3) By Applications: Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications _x000D_
_x000D_
Subsegments:_x000D_
1) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG) _x000D_
2) By Albumin: Human Serum Albumin, Recombinant Albumin _x000D_
3) By Coagulation Factor: Factor VIII, Factor IX, Prothrombin Complex Concentrates_x000D_
4) By C1-Esterase Inhibitors: Human C1-Esterase Inhibitors, Recombinant C1-Esterase Inhibitors _x000D_
5) By Other Products: Fibrinogen, Alpha-1 Antitrypsin, Clotting Factor Concentrates _x000D_
_x000D_
#Plasma Protein Therapeutics Market Industry Trends Fueling Future Revenue Growth#_x000D_
Leading companies in the plasma protein therapeutics market are concentrating on developing innovative solutions, such as lyophilized plasma formulations, to fulfill the increasing need for portable, stable, and quick-to-use blood products in emergency and pre-hospital medical environments. These freeze-dried plasma products offer an extended shelf life, simpler storage, and faster reconstitution compared to conventional frozen plasma, making them highly suitable for trauma, emergency medicine, and field settings. For instance, in October 2023, Octapharma AG, a Switzerland-based pharmaceutical company, secured approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation facilitates convenient pre-hospital transfusion, providing rapid availability, simplified handling, and enhanced stability for critical care situations. The product supports the effective management of trauma and bleeding emergencies, showcasing Octapharma’s dedication to advancing patient care through innovative plasma-based therapies._x000D_
_x000D_
#Plasma Protein Therapeutics Market Leading Players And Competitive Positioning#_x000D_
Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG _x000D_
_x000D_
#View The Full Plasma Protein Therapeutics Market Report:#_x000D_
_x000D_
#Plasma Protein Therapeutics Market Regional Analysis And Top Geography#_x000D_
North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
